PP2A-mediated anticancer therapy

Gastroenterology Research and Practice

Volumn 2013, Issue , 2013, Pages

  Chen, Weibo ^a,b   Wang, Zhongxia ^a,b   Jiang, Chunping ^a,b   Ding, Yitao ^a,b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b Jiangsu Province's Key Medical Center for Hepatobiliary Disease   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL DERIVATIVE; BORTEZOMIB; CARNOSIC ACID; CERAMIDE; CHLOROETHYLNITROSOUREA; COG 112; E1A PROTEIN; ERLOTINIB; FINGOLIMOD; FORSKOLIN; JACALIN; METHYLPREDNISOLONE; PEPTIDE; PHOSPHOPROTEIN PHOSPHATASE 2A; SILIBININ; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER PATIENT; CANCER RESISTANCE; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PERMEABILIZATION; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; DEPHOSPHORYLATION; DNA REPLICATION; DOWN REGULATION; ENZYME ACTIVE SITE; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; EVENT FREE SURVIVAL; GENE DELETION; HAPLOINSUFFICIENCY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LEUKEMIA; LEUKEMOGENESIS; LUNG CANCER; MALIGNANT TRANSFORMATION; MELANOMA; METHYLATION; NEPHROBLASTOMA; NONHUMAN; ONCOGENE C MYC; OVARY CANCER; OVERALL SURVIVAL; PHENOTYPE; POINT MUTATION; POSTSYNAPTIC DENSITY; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN QUATERNARY STRUCTURE; REVIEW; TANDEM REPEAT; TRIPLE NEGATIVE BREAST CANCER; UTERINE CERVIX CANCER; WNT SIGNALING PATHWAY;

EID: 84888871942     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2013/675429     Document Type: Review

References (86)

1. Janssens V., Goris J., Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochemical Journal 2001 353 3 417 439 2-s2.0-0035252894 10.1042/0264-6021: 3530417 (Pubitemid 32158309)
2. Virshup D. M., Protein phosphatase 2A: a panoply of enzymes. Current Opinion in Cell Biology 2000 12 2 180 185 2-s2.0-0034009389 10.1016/S0955- 0674(99)00074-5 (Pubitemid 30142564)
3. Schönthal A. H., Role of serine/threonine protein phosphatase 2A in cancer. Cancer Letters 2001 170 1 1 13 2-s2.0-0035840446 10.1016/S0304-3835(01) 00561-4 (Pubitemid 32607654)
4. van Cutsem E., Köhne C.-H., Hitre E., Zaluski J., Chien C.-R. C., Makhson A., D'Haens G., Pintér T., Lim R., Bodoky G., Roh J. K., Folprecht G., Ruff P., Stroh C., Tejpar S., Schlichting M., Nippgen J., Rougier P., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine 2009 360 14 1408 1417 2-s2.0-63849088630 10.1056/NEJMoa0805019
5. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Global cancer statistics. CA: Cancer Journal for Clinicians 2011 61 2 69 90 2-s2.0-79952232216 10.3322/caac.20107
6. Perz J. F., Armstrong G. L., Farrington L. A., Hutin Y. J. F., Bell B. P., The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology 2006 45 4 529 538 2-s2.0-33748114343 10.1016/j.jhep.2006.05.013 (Pubitemid 44307383)
7. Guo H., Reddy S. A. G., Damuni Z., Purification and characterization of an autophosphorylation-activated protein serine threonine kinase that phosphorylates and inactivates protein phosphatase 2A. Journal of Biological Chemistry 1993 268 15 11193 11198 2-s2.0-0027319625 (Pubitemid 23162311)
8. Janssens V., Longin S., Goris J., PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends in Biochemical Sciences 2008 33 3 113 121 2-s2.0-39949083195 10.1016/j.tibs.2007.12.004
9. Brautigan D. L., Flicking the switches: phosphorylation of serine/threonine protein phosphatases. Seminars in Cancer Biology 1995 6 4 211 217 2-s2.0-0029349353
10. Favre B., Zolnierowicz S., Turowski P., Hemmings B. A., The catalytic subunit of protein phosphatase 2A is carboxyl-methylated in vivo. Journal of Biological Chemistry 1994 269 23 16311 16317 2-s2.0-0028361380 (Pubitemid 24209328)
11. Cho U. S., Xu W., Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature 2007 445 7123 53 57 2-s2.0-33846118688 10.1038/nature05351 (Pubitemid 46067298)
12. Sablina A. A., Chen W., Arroyo J. D., Corral L., Hector M., Bulmer S. E., DeCaprio J. A., Hahn W. C., The tumor suppressor PP2A A β regulates the RalA GTPase. Cell 2007 129 5 969 982 2-s2.0-34249291096 10.1016/j.cell.2007.03. 047 (Pubitemid 46813152)
13. Wang S. S., Esplin E. D., Li J. L., Huang L., Gazdar A., Minna J., Evans G. A., Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998 282 5387 284 287 2-s2.0-0032500792 10.1126/science.282.5387.284 (Pubitemid 28487198)
14. Calin G. A., di Iasio M. G., Caprini E., Vorechovsky I., Natali P. G., Sozzi G., Croce C. M., Barbanti-Brodano G., Russo G., Negrini M., Low frequency of alterations of the α (PPP2R1A) and β (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene 2000 19 9 1191 1195 2-s2.0-0034708257 (Pubitemid 30157549)
15. Ruediger R., Pham H. T., Walter G., Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A β subunit gene. Oncogene 2001 20 15 1892 1899 2-s2.0-0035810043 10.1038/sj.onc.1204279 (Pubitemid 32458699)
16. Sablina A. A., Hahn W. C., The role of PP2A A subunits in tumor suppression. Cell Adhesion & Migration 2007 1 3 140 141 2-s2.0-66549085133
17. Ruediger R., Pham H. T., Walter G., Disruption of protein phosphatase 2a subunit interaction in human cancers with mutations in the A α subunit gene. Oncogene 2001 20 1 10 15 2-s2.0-0035804217 (Pubitemid 32142333)
18. Chen W., Possemato R., Campbell K. T., Plattner C. A., Pallas D. C., Hahn W. C., Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 2004 5 2 127 136 2-s2.0-1442310493 10.1016/S1535-6108(04)00026-1 (Pubitemid 38283799)
19. Chen W., Arroyo J. D., Timmons J. C., Possemato R., Hahn W. C., Cancer-associated PP2A A α subunits induce functional haploinsufficiency and tumorigenicity. Cancer Research 2005 65 18 8183 8192 2-s2.0-24944485819 10.1158/0008-5472.CAN-05-1103 (Pubitemid 41330582)
20. McCright B., Rivers A. M., Audlin S., Virshup D. M., The B56 family of protein phosphatase 2A (PP2A) regulatory subunits encodes differentiation- induced phosphoproteins that target PP2A to both nucleus and cytoplasm. Journal of Biological Chemistry 1996 271 36 22081 22089 2-s2.0-0029834655 10.1074/jbc.271.36.22081 (Pubitemid 26303837)
21. Voorhoeve P. M., Hijmans E. M., Bernards R., Functional interaction between a novel protein phosphatase 2A regulatory subunit, PR59, and the retinoblastoma-related p107 protein. Oncogene 1999 18 2 515 524 2-s2.0-0033552957 10.1038/sj.onc.1202316 (Pubitemid 29060627)
22. Moreno C. S., Park S., Nelson K., Ashby D., Hubalek F., Lane W. S., Pallas D. C., WD40 repeat proteins striatin and S/G2 nuclear autoantigen are members of a novel family of calmodulin-binding proteins that associate with protein phosphatase 2A. Journal of Biological Chemistry 2000 275 8 5257 5263 2-s2.0-0034050449 10.1074/jbc.275.8.5257 (Pubitemid 30115152)
23. Deichmann M., Polychronidis M., Wacker J., Thome M., Näher H., The protein phosphatase 2A subunit B γ gene is identified to be differentially expressed in malignant melanomas by subtractive suppression hybridization. Melanoma Research 2001 11 6 577 585 2-s2.0-0035216768 10.1097/00008390- 200112000-00004 (Pubitemid 33152349)
24. Ito A., Kataoka T. R., Watanabe M., Nishiyama K., Mazaki Y., Sabe H., Kitamura Y., Nojima H., A truncated isoform of the PP2A B56 subunit promotes cell motility through paxillin phosphorylation. EMBO Journal 2000 19 4 562 571 2-s2.0-0034651747 (Pubitemid 30093729)
25. Perrotti D., Neviani P., Protein phosphatase 2A: a target for anticancer therapy. The Lancet Oncology 2013 14 6 e229 e238 10.1016/S1470-2045(12)70558-2
26. Dong Q.-Z., Wang Y., Dong X.-J., Li Z.-X., Tang Z.-P., Cui Q.-Z., Wang E.-H., CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Annals of Surgical Oncology 2011 18 3 857 865 2-s2.0-79955739210 10.1245/s10434-010-1313-8
27. Vaarala M. H., Vaisanen M.-R., Ristimaki A., CIP2A expression is increased in prostate cancer. Journal of Experimental & Clinical Cancer Research 2010 29, article 136 10.1186/1756-9966-29-136
28. Wang J., Li W., Li L., Yu X., Jia J., Chen C., CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. International Journal of Laboratory Hematology 2011 33 3 290 298 2-s2.0-79952925941 10.1111/j.1751-553X.2010.01288.x
29. Arroyo J. D., Hahn W. C., Involvement of PP2A in viral and cellular transformation. Oncogene 2005 24 52 7746 7755 2-s2.0-27944448894 10.1038/sj.onc.1209038 (Pubitemid 41670676)
30. Junttila M. R., Westermarck J., Mechanisms of MYC stabilization in human malignancies. Cell Cycle 2008 7 5 592 596 2-s2.0-41849140001 (Pubitemid 351498996)
31. Junttila M. R., Puustinen P., Niemelä M., Ahola R., Arnold H., Böttzauw T., Ala-aho R., Nielsen C., Ivaska J., Taya Y., Lu S.-L., Lin S., Chan E. K. L., Wang X.-J., Grènman R., Kast J., Kallunki T., Sears R., Kähäri V.-M., Westermarck J., CIP2A Inhibits PP2A in human malignancies. Cell 2007 130 1 51 62 2-s2.0-34447283580 10.1016/j.cell.2007.04. 044 (Pubitemid 47039258)
32. Tseng L.-M., Liu C.-Y., Chang K.-C., Chu P.-Y., Shiau C.-W., Chen K.-F., CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Research 2012 14 2, article R68 2-s2.0-84860130283 10.1186/bcr3175
33. Lin Y.-C., Chen K.-C., Chen C.-C., Cheng A.-L., Chen K.-F., CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncology 2012 48 7 585 593 2-s2.0-84856830347 10.1016/j.oraloncology.2012.01.012
34. Chen K.-F., Liu C.-Y., Lin Y.-C., Yu H.-C., Liu T.-H., Hou D.-R., Chen P.-J., Cheng A.-L., CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010 29 47 6257 6266 2-s2.0-78649511007 10.1038/onc.2010.357
35. Liu C.-Y., Shiau C.-W., Kuo H.-Y., Huang H.-P., Chen M.-H., Tzeng C.-H., Chen K.-F., Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells. Haematologica 2013 98 5 729 738 10.3324/haematol.2011.050187
36. Huang C.-Y., Wei C.-C., Chen K.-C., Chen H.-J., Cheng A.-L., Chen K.-F., Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A. Cancer Letters 2012 317 1 9 15 2-s2.0-84856343866 10.1016/j.canlet.2011. 11.005
37. Yu H.-C., Hou D.-R., Liu C.-Y., Lin C.-S., Shiau C.-W., Cheng A.-L., Chen K.-F., Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome. PLoS ONE 2013 8 2 e55705
38. Yu H.-C., Chen H.-J., Chang Y.-L., Liu C.-Y., Shiau C.-W., Cheng A.-L., Chen K.-F., Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma. Biochemical Pharmacology 2013 85 3 356 366 10.1016/j.bcp.2012.11.009
39. Li M., Makkinje A., Damuni Z., The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. Journal of Biological Chemistry 1996 271 19 11059 11062 2-s2.0-0029889342 10.1074/jbc.271.19.11059 (Pubitemid 26155931)
40. Yu L.-G., Packman L. C., Weldon M., Hamlett J., Rhodes J. M., Protein phosphatase 2A, a negative regulator of the ERK signaling pathway, is activated by tyrosine phosphorylation of putative HLA class II-associated protein I (PHAPI)/pp32 in response to the antiproliferative lectin, jacalin. Journal of Biological Chemistry 2004 279 40 41377 41383 2-s2.0-4744352601 10.1074/jbc.M400017200 (Pubitemid 39313577)
41. Switzer C. H., Cheng R. Y. S., Vitek T. M., Christensen D. J., Wink D. A., Vitek M. P., Targeting SET/I2 PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 2011 30 22 2504 2513 2-s2.0-79957910918 10.1038/onc.2010.622
42. Fan Z., Beresford P. J., Oh D. Y., Zhang D., Lieberman J., Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein set is its inhibitor. Cell 2003 112 5 659 672 2-s2.0-0037423932 10.1016/S0092-8674(03)00150-8 (Pubitemid 36331778)
43. Eichhorn P. J. A., Creyghton M. P., Bernards R., Protein phosphatase 2A regulatory subunits and cancer. Biochimica et Biophysica Acta 2009 1795 1 1 15 2-s2.0-58049186804 10.1016/j.bbcan.2008.05.005
44. Christensen D. J., Ohkubo N., Oddo J., van Kanegan M. J., Neil J., Li F., Colton C. A., Vitek M. P., Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. The Journal of Immunology 2011 186 4 2535 2542 2-s2.0-79951830539 10.4049/jimmunol.1002847
45. Cristóbal I., Blanco F. J., Garcia-Orti L., Marcotegui N., Vicente C., Rifon J., Novo F. J., Bandres E., Calasanz M. J., Bernabeu C., Odero M. D., SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood 2010 115 3 615 625 2-s2.0-77449131060 10.1182/blood-2009-06-227363
46. Cristóbal I., Garcia-Orti L., Cirauqui C., Cortes-Lavaud X., García-Sánchez M. A., Calasanz M. J., Odero M. D., Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica 2012 97 4 543 550 2-s2.0-84859449771 10.3324/haematol.2011.050542
47. Piazza R., Valletta S., Winkelmann N., Redaelli S., Spinelli R., Pirola A., Antolini L., Mologni L., Donadoni C., Papaemmanuil E., Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nature Genetics 2012 45 1 18 24 10.1038/ng.2495
48. Lin C.-F., Chen C.-L., Chiang C.-W., Jan M.-S., Huang W.-C., Lin Y.-S., GSK-3 β acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 in ceramide-induced mitochondrial apoptosis. Journal of Cell Science 2007 120 16 2935 2943 2-s2.0-34548568958 10.1242/jcs.03473 (Pubitemid 47394267)
49. Kim S. W., Kim H. J., Chun Y. J., Kim M. Y., Ceramide produces apoptosis through induction of p27kip1 by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells. Journal of Toxicology and Environmental Health A 2010 73 21-22 1465 1476 2-s2.0-77958168429 10.1080/15287394.2010.511553
50. Azuma H., Takahara S., Ichimaru N., Wang J. D., Itoh Y., Otsuki Y., Morimoto J., Fukui R., Hoshiga M., Ishihara T., Nonomura N., Suzuki S., Okuyama A., Katsuoka Y., Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Research 2002 62 5 1410 1419 2-s2.0-0036494268 (Pubitemid 34407800)
51. Matsuoka Y., Nagahara Y., Ikekita M., Shinomiya T., A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. British Journal of Pharmacology 2003 138 7 1303 1312 2-s2.0-0037739755 10.1038/sj.bjp.0705182 (Pubitemid 36543128)
52. Neviani P., Harb J. G., Oaks J. J., Walker C., Santhanam R., Paisie C., Eiring A., Zhang B., Perazzona B., Ma Y., BCR-ABL1 kinase activity but not its expression is dispensable for Ph plus quiescent stem cell survival which depends on the PP2A-controlled Jak2 activation and is sensitive to FTY720 treatment. Blood: 2010 2010 Washington, DC, USA The American Society of Hematology 227 228
53. Liao Y., Hung M.-C., A new role of protein phosphatase 2A in adenoviral E1A protein-mediated sensitization to anticancer drug-induced apoptosis in human breast cancer cells. Cancer Research 2004 64 17 5938 5942 2-s2.0-4344686261 10.1158/0008-5472.CAN-04-1533 (Pubitemid 39129388)
54. Sontag E., Protein phosphatase 2A: the trojan horse of cellular signaling. Cellular Signalling 2001 13 1 7 16 2-s2.0-0035100658 10.1016/S0898-6568(00)00123-6 (Pubitemid 32222967)
55. Ruteshouser E. C., Ashworth L. K., Huff V., Absence of PPP2R1A mutations in Wilms tumor. Oncogene 2001 20 16 2050 2054 2-s2.0-0035848717 10.1038/sj.onc.1204301 (Pubitemid 32458037)
56. Schöls L., Amoiridis G., Büttner T., Przuntek H., Epplen J. T., Riess O., Autosomal dominant cerebellar ataxia: phenotypic differences in genetically defined subtypes? Annals of Neurology 1997 42 6 924 932 2-s2.0-2642589007 10.1002/ana.410420615 (Pubitemid 28008424)
57. Hu P., Yu L., Zhang M., Zheng L., Zhao Y., Fu Q., Zhao S., Molecular cloning and mapping of the brain-abundant B1 γ subunit of protein phosphatase 2A, PPP2R2C, to human chromosome 4p16. Genomics 2000 67 1 83 86 2-s2.0-0034234384 10.1006/geno.2000.6219 (Pubitemid 30471124)
58. McCright B., Brothman A. R., Virshup D. M., Assignment of human protein phosphatase 2A regulatory subunit genes B56 α B56 β B56 γ B56 δ and B56 ε (PPP2R5A-PPP2R5E), highly expressed in muscle and brain, to chromosome regions 1q41, 11q12, 3p21, 6p21.1, and 7p11.2 → p12. Genomics 1996 36 1 168 170 2-s2.0-0030586955 10.1006/geno.1996.0438 (Pubitemid 26277771)
59. Seshacharyulu P., Pandey P., Datta K., Batra S. K., Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Letters 2013 335 1 9 18 10.1016/j.canlet.2013.02.036
60. Jones T. A., Barker H. M., Da Cruz Silva E. E. F., Mayer-Jaekel R. E., Hemmings B. A., Spurr N. K., Sheer D., Cohen P. T. W., Localization of the genes encoding the catalytic subunits of protein phosphatase 2A to human chromosome bands 5q23→q31 and 8p12→p11.2, respectively. Cytogenetics and Cell Genetics 1993 63 1 35 41 2-s2.0-0027471688 (Pubitemid 23102319)
61. Ruediger R., Zhou J., Walter G., Moorhead G., Mutagenesis and expression of the scaffolding A α and A β subunits of PP2A. Protein Phosphatase Protocols 2007 365 85 99 Methods in Molecular Biology 10.1385/1-59745-267-X:85
62. Cristóbal I., Garcia-Orti L., Cirauqui C., Alonso M. M., Calasanz M. J., Odero M. D., PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 2011 25 4 606 614 2-s2.0-79954449794 10.1038/leu.2010.294
63. Feschenko M. S., Stevenson E., Nairn A. C., Sweadner K. J., A novel cAMP-stimulated pathway in protein phosphatase 2A activation. Journal of Pharmacology and Experimental Therapeutics 2002 302 1 111 118 2-s2.0-0036085455 10.1124/jpet.302.1.111 (Pubitemid 34680428)
64. Guénin S., Schwartz L., Morvan D., Steyaert J. M., Poignet A., Madelmont J. C., Demidem A., PP2A activity is controlled by methylation and regulates oncoprotein expression in melanoma cells: a mechanism which participates in growth inhibition induced by chloroethylnitrosourea treatment. International Journal of Oncology 2008 32 1 49 57 2-s2.0-38749091638 (Pubitemid 351176061)
65. Madhunapantula S. V., Mosca P. J., Robertson G. P., The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biology & Therapy 2011 12 12 1032 1049 2-s2.0-84055199840 10.4161/cbt.12.12.18442
66. Huang P.-H., Wang D., Chuang H.-C., Wei S., Kulp S. K., Chen C.-S., α -tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis. Carcinogenesis 2009 30 7 1125 1131 2-s2.0-67650178047 10.1093/carcin/bgp112
67. Neuzil J., Weber T., Schröder A., Lu M., Ostermann G., Gellert N., Mayne G. C., Olejnicka B., Nègre-Salvayre A., Stícha M., Coffey R. J., Weber C., Induction of cancer cell apoptosis by α -tocopheryl succinate: molecular pathways and structural requirements. The FASEB Journal 2001 15 2 403 415 2-s2.0-17744376942 10.1096/fj.00-0251com (Pubitemid 32141432)
68. Kar S., Palit S., Ball W. B., Das P. K., Carnosic acid modulates Akt/IKK/NF- B signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells. Apoptosis 2012 17 7 735 747 2-s2.0-84858716024 10.1007/s10495-012-0715-4
69. Uzunoglu S., Uslu R., Tobu M., Saydam G., Terzioglu E., Buyukkececi F., Omay S. B., Augmentation of methylprednisolone-induced differentiation of myeloid leukemia cells by serine/threonine protein phosphatase inhibitors. Leukemia Research 1999 23 5 507 512 2-s2.0-0032900722 10.1016/S0145-2126(99) 00040-5 (Pubitemid 29223080)
70. Switzer C. H., Ridnour L. A., Cheng R. Y. S., Sparatore A., del Soldato P., Moody T. W., Vitek M. P., Roberts D. D., Wink D. A., Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity. Oncogene 2009 28 43 3837 3846 2-s2.0-70350690313 10.1038/onc.2009.244
71. Tan J., Lee P. L., Li Z., Jiang X., Lim Y. C., Hooi S. C., Yu Q., B55 β -associated PP2A complex controls PDK1-directed Myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell 2010 18 5 459 471 2-s2.0-78249287240 10.1016/j.ccr.2010.10.021
72. Lin S.-P., Lee Y.-T., Yang S.-H., Miller S. A., Chiou S.-H., Hung M.-C., Hung S.-C., Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis. Cancer Letters 2013 328 2 226 234 10.1016/j.canlet.2012.08.036
73. Lu J., Zhuang Z., Song D. K., Mehta G. U., Ikejiri B., Mushlin H., Park D. M., Lonser R. R., The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma: laboratory investigation. Journal of Neurosurgery 2010 113 2 225 233 2-s2.0-77955595320 10.3171/2009.11.JNS091272
74. Wang J.-Y., Chang C.-C., Chiang C.-C., Chen W.-M., Hung S.-C., Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways. Journal of Cellular Biochemistry 2012 113 5 1733 1743 2-s2.0-84859076999 10.1002/jcb.24043
75. Kumar A., Pandurangan A. K., Lu F., Fyrst H., Zhang M., Byun H.-S., Bittman R., Saba J. D., Chemopreventive sphingadienes downregulate Wnt signaling via a PP2A/Akt/GSK3 β pathway in colon cancer. Carcinogenesis 2012 33 9 1726 1735 10.1093/carcin/bgs174
76. Reya T., Clevers H., Wnt signalling in stem cells and cancer. Nature 2005 434 7035 843 850 2-s2.0-17244376814 10.1038/nature03319 (Pubitemid 40558990)
77. Bos C. L., Kodach L. L., Van den Brink G. R., Diks S. H., van Santen M. M., Richel D. J., Peppelenbosch M. P., Hardwick J. C. H., Effect of aspirin on the Wnt/ β -catenin pathway is mediated via protein phosphatase 2A. Oncogene 2006 25 49 6447 6456 2-s2.0-33750223793 10.1038/sj.onc.1209658 (Pubitemid 44607077)
78. Bos C. L., Diks S. H., Hardwick J. C. H., Walburg K. V., Peppelenbosch M. P., Richel D. J., Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/ β -catenin pathway activity. Carcinogenesis 2006 27 12 2371 2382 2-s2.0-33845352518 10.1093/carcin/bgl071 (Pubitemid 44884094)
79. Guichard C., Pedruzzi E., Fay M., Marie J.-C., Braut-Boucher F., Daniel F., Grodet A., Gougerot-Pocidalo M.-A., Chastre E., Kotelevets L., Lizard G., Vandewalle A., Driss F., Ogier-Denis E., Dihydroxyphenylethanol induces apoptosis by activating serine/threonine protein phosphatase PP2A and promotes the endoplasmic reticulum stress response in human colon carcinoma cells. Carcinogenesis 2006 27 9 1812 1827 2-s2.0-33747891922 10.1093/carcin/bgl009 (Pubitemid 44288663)
80. Chen K. F., Pao K. C., Su J. C., Chou Y. C., Liu C. Y., Chen H. J., Huang J. W., Kim I., Shiau C. W., Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorganic & Medicinal Chemistry 2012 20 20 6144 6153 10.1016/j.bmc.2012.08.039
81. Dung T. D., Day C. H., Binh T. V., Lin C.-H., Hsu H.-H., Su C.-C., Lin Y.-M., Tsai F.-J., Kuo W.-W., Chen L.-M., Huang C.-Y., PP2A mediates diosmin p53 activation to block HA22T cell proliferation and tumor growth in xenografted nude mice through PI3K-Akt-MDM2 signaling suppression. Food and Chemical Toxicology 2012 50 5 1802 1810 2-s2.0-84859364854 10.1016/j.fct.2012.01.021
82. Dung T. D., Chang H.-C., Binh T. V., Lee M.-R., Tsai C.-H., Tsai F.-J., Kuo W.-W., Chen L.-M., Huang C.-Y., Zanthoxylum avicennae extracts inhibit cell proliferation through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells in vitro and in vivo. International Journal of Molecular Medicine 2012 29 6 1045 1052 2-s2.0-84860542258 10.3892/ijmm.2012.938
83. Bialojan C., Takai A., Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochemical Journal 1988 256 1 283 290 2-s2.0-0023691731
84. Zimmerman R., Peng D., Lanz H., Zhang Y., Danen-van Oorschot A., Qu S., Backendorf C., Noteborn M., PP2A inactivation is a crucial step in triggering apoptin-induced tumor-selective cell killing. Cell Death & Disease 2012 3 4, article e291
85. Honkanen R. E., Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Letters 1993 330 3 283 286 2-s2.0-0027217027 10.1016/0014-5793(93)80889-3 (Pubitemid 23276340)
86. Li W., Chen Z., Zong Y., Gong F., Zhu Y., Zhu Y., Lv J., Zhang J., Xie L., Sun Y., Miao Y., Tao M., Han X., Xu Z., PP2A inhibitors induce apoptosis in pancreatic cancer cell line PANC-1 through persistent phosphorylation of IKK α and sustained activation of the NF- B pathway. Cancer Letters 2011 304 2 117 127 2-s2.0-79952739700 10.1016/j.canlet.2011.02.009